Zoetis
ZTS
$72.97
+0.15%
Zoetis Inc. is the world's largest animal health company, discovering, developing, and commercializing vaccines, anti-infectives, parasiticides, diagnostics, and other health products for companion animals (dogs, cats, horses) and production animals (cattle, swine, poultry, fish), operating in the global animal health industry. Spun off from Pfizer in 2013, the company holds the largest market share in animal health, with roughly 65% of revenue from companion animals and 35% from production animals, and its US business skewed even more heavily toward the higher-margin companion animal segment. The current investor narrative has turned sharply negative: after a long run as a premium-quality compounder, the stock suffered a severe single-day collapse in early May 2026 (from roughly $111 to $87, then to the mid-$70s within days), and a February 2026 Benzinga headline captured the debate — analysts are questioning Zoetis' pathway to growth as key segments slide, despite an EPS beat and strong 2026 guidance. The market is now debating whether this is a temporary dislocation in a still-profitable category leader or the beginning of a structural slowdown in companion animal spending, with the stock down more than 50% over the past year while the S&P 500 gained over 16%.…
ZTS
Zoetis
$72.97
Related headlines
Investment Opinion: Should I buy ZTS Today?
The synthesized recommendation is a Hold with a contrarian tilt toward Buy for risk-tolerant investors. The core thesis is that Zoetis remains a highly profitable market leader trading at a deep discount to its historical valuation and analyst targets, but the severe growth deceleration and negative momentum warrant caution until there are clear signs of stabilization. The analyst consensus rating of 2.22 (Buy) and average target price of $96.00 imply 31.6% upside, but these targets may be stale given the recent collapse.
The supporting evidence for a Hold/Buy includes: 1) A forward P/E of 11.17x, which is less than half the trailing P/E of 20.87x and suggests the market expects earnings to decline; 2) A gross margin of 70.5% and net margin of 28.2%, demonstrating strong pricing power and cost control; 3) $2.14B in trailing free cash flow, providing ample resources for dividends (1.59% yield) and buybacks; and 4) A low beta of 0.729, which offers defensive characteristics. However, revenue growth of just 1.89% year-over-year is a red flag, and the debt-to-equity ratio of 2.85 is a concern.
The biggest risks that could invalidate the thesis are a continued decline in companion animal spending, further revenue deceleration, and a potential dividend cut if cash flow deteriorates. The rating would upgrade to Buy if revenue growth reaccelerates above 5% or if the stock stabilizes above $80 with improving sentiment. It would downgrade to Sell if revenue growth turns negative or if the company cuts its dividend. Relative to its history and peers, ZTS appears undervalued on a forward earnings basis but may be fairly valued on a trailing basis given the growth challenges. The stock is not a screaming buy, but the risk/reward is becoming more balanced for long-term investors.
Sign up to view all
ZTS 12-Month Price Forecast
The forward-looking view is cautiously neutral, balancing deep value against significant growth concerns. The stock's 11x forward P/E and 32% analyst upside are attractive, but the severe revenue deceleration and negative momentum suggest the market is pricing in a structural slowdown. The low beta and strong margins provide some downside protection, but the high debt-to-equity ratio and premium price-to-book ratio limit the margin of safety. I would upgrade to bullish if revenue growth reaccelerates above 4% or if the stock stabilizes above $80 with improving relative strength. I would downgrade to bearish if revenue growth turns negative or if the company cuts its dividend.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zoetis's 12-month outlook, with a consensus price target around $96.00 and implied upside of +31.6% versus the current price.
Average Target
$96.00
0 analysts
Implied Upside
+31.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $155
Analyst target range
Bulls vs Bears: ZTS Investment Factors
The bear case currently has stronger evidence due to the severe price collapse, decelerating revenue growth, and massive relative underperformance. However, the bull case rests on compelling valuation and profitability metrics that suggest the sell-off may be overdone. The single most important tension is whether the companion animal spending slowdown is a cyclical pause or a structural shift; if it's cyclical, the stock is deeply undervalued, but if structural, further downside is likely. The market is clearly betting on the latter, but the 11x forward P/E and 32% analyst upside imply a potential asymmetric risk/reward for contrarian investors.
Bullish
- Deep Value on Forward Earnings: ZTS trades at a forward P/E of just 11.17x based on estimated EPS of $9.06, a dramatic discount to its historical premium multiple and to the broader healthcare sector. This suggests the market has priced in a severe earnings decline that may not materialize given the company's 28.2% net margin and $2.14B in trailing free cash flow.
- Analyst Consensus Sees 32% Upside: The average analyst target price is $96.00, implying 31.6% upside from the current $72.97, with a 'buy' consensus rating (mean 2.22) from 15 analysts. Even the lowest target of $80.00 represents a 9.6% gain, indicating that professional analysts view the sell-off as overdone.
- Fortress Balance Sheet and Profitability: Zoetis generates a 70.5% gross margin, 38.0% operating margin, and 28.2% net margin, with a current ratio of 3.03 and $2.14B in trailing free cash flow. These metrics reflect a highly profitable business with ample liquidity to weather near-term headwinds.
- Low Beta Defensive Characteristics: With a beta of 0.729, ZTS is significantly less volatile than the broader market, making it an attractive defensive holding in uncertain macro environments. The stock's 1-month relative strength of +0.28% versus the S&P 500 suggests it may be stabilizing after a prolonged decline.
Bearish
- Catastrophic Price Collapse: ZTS has plummeted 51.6% over the past year and 42.1% year-to-date, with a max drawdown of -54.2%. The stock fell from $111 to $87 in a single day in May 2026 and has continued to grind lower, closing at $72.97, just 2.8% above its 52-week low of $71.00.
- Growth Has Stalled: Q1 2026 revenue grew just 1.89% year-over-year to $2.262B, a sharp deceleration from historical double-digit growth. This slowdown, combined with declining growth in key segments, has raised questions about the company's competitive positioning and long-term growth trajectory.
- Extreme Relative Underperformance: ZTS has underperformed the S&P 500 by 67.8 percentage points over the past year and by 54.1 percentage points year-to-date. This severe relative weakness indicates a fundamental shift in investor sentiment and potential structural issues rather than a temporary dip.
- High Leverage and Stretched Valuation Metrics: The debt-to-equity ratio stands at 2.85, and the price-to-book ratio is an elevated 16.75. While the forward P/E is low, the trailing P/E of 20.87 and PEG of 2.04 suggest that even after the crash, the stock is not statistically cheap relative to its growth rate.
ZTS Technical Analysis
Beta
0.73
0.73x market volatility
Max Drawdown
-54.2%
Largest decline past year
52-Week Range
$71-$150
Price range past year
Annual Return
-51.6%
Cumulative gain past year
| Period | ZTS Return | S&P 500 |
|---|---|---|
| 1m | -0.8% | -1.6% |
| 3m | -8.3% | +1.3% |
| 6m | -36.9% | +13.9% |
| 1y | -51.6% | +16.3% |
| ytd | -42.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZTS Fundamental Analysis
Quarterly Revenue
$2.3B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
71.7%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZTS Overvalued?
PE
20.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Zoetis faces significant financial and operational risks that have been magnified by the recent collapse. The debt-to-equity ratio of 2.85 is elevated, and while the current ratio of 3.03 provides liquidity, the company's $62 million quarterly interest expense consumes a meaningful portion of operating income. More critically, revenue growth has decelerated to just 1.89% year-over-year in Q1 2026, down from historical double-digit rates, and the company's heavy reliance on companion animal products (65% of revenue) exposes it to a potential slowdown in discretionary pet spending. The 28.2% net margin, while strong, could compress if competitive pressures intensify or if the company needs to increase promotional spending to defend market share.
Market and competitive risks are substantial given the stock's extreme underperformance and premium valuation metrics. The price-to-book ratio of 16.75 and trailing P/E of 20.87 are high for a company with sub-2% revenue growth, and the PEG ratio of 2.04 suggests the market is still paying up for growth that may not materialize. The beta of 0.729 indicates lower volatility than the market, but this has not protected the stock from a 51.6% one-year decline. The February 2026 Benzinga article highlights analyst concerns about the pathway to growth as key segments slide, and competitive threats from generic alternatives and other animal health players could further erode Zoetis' market share. Additionally, the stock's 67.8% relative underperformance versus the S&P 500 over the past year suggests it is out of favor and could remain so if sector rotation continues to favor other areas.
The worst-case scenario for ZTS would be a continued deterioration in companion animal spending, leading to further revenue declines and margin compression. If the company's growth remains stagnant or turns negative, the forward P/E of 11.17x could prove to be a value trap, and the stock could test its 52-week low of $71.00 or even fall below it. From the current price of $72.97, a drop to the 52-week low represents a 2.7% loss, but if the bear case fully materializes and the stock re-rates to a more appropriate multiple for a no-growth business, it could fall to the analyst low target of $80.00 (which is actually above the current price) or lower. A more realistic downside scenario might see the stock decline another 20-30% to the $50-$58 range if earnings estimates are revised downward, representing a total drawdown of over 60% from the 52-week high of $150.05.
FAQ
The key risks for ZTS are ranked by severity: 1) Growth risk: Revenue growth has decelerated to 1.89% year-over-year, and if it turns negative, the stock could fall below its 52-week low of $71.00. 2) Financial risk: The debt-to-equity ratio of 2.85 is high, and interest expense of $62 million per quarter consumes a significant portion of operating income. 3) Competitive risk: The company faces threats from generic alternatives and other animal health players, which could erode its 65% companion animal revenue base. 4) Macro risk: A recession could reduce discretionary spending on pets, and the stock's beta of 0.729 does not fully insulate it from market downturns. Additionally, the dividend yield of 1.59% could be at risk if cash flow deteriorates.
The 12-month forecast for ZTS includes three scenarios: a base case (50% probability) with a target range of $80-$96, assuming revenue growth stabilizes in the low single digits; a bull case (25% probability) with a target range of $96-$155, driven by new product launches and a rebound in companion animal spending; and a bear case (25% probability) with a target range of $50-$71, if revenue growth turns negative and the company misses earnings. The most likely scenario is the base case, where the stock trades sideways to modestly higher as the market awaits clearer signs of a turnaround. The key assumption is that forward EPS of $9.06 is achieved, supporting an 11-12x multiple.
ZTS appears undervalued on a forward earnings basis, with a forward P/E of 11.17x compared to a trailing P/E of 20.87x and a price-to-book ratio of 16.75. The market is pricing in a significant earnings decline, which may be overly pessimistic given the company's 28.2% net margin and $2.14B in free cash flow. However, the PEG ratio of 2.04 suggests that even after the crash, the stock is not cheap relative to its growth rate. Compared to its own history, the forward P/E is near multi-year lows, but the premium price-to-book ratio indicates that the market still values the company's intangible assets and market leadership. Overall, the stock is fairly valued to slightly undervalued, with the potential for multiple expansion if growth stabilizes.
ZTS presents a high-risk, high-reward opportunity that is not suitable for all investors. The stock trades at a forward P/E of 11.17x, implying 31.6% upside to the average analyst target of $96.00, and offers a 1.59% dividend yield. However, the company's revenue growth has slowed to 1.89% year-over-year, and the stock has fallen 51.6% over the past year, indicating significant headwinds. For contrarian value investors with a long time horizon, the risk/reward may be attractive, but conservative investors should wait for clearer signs of a turnaround, such as revenue growth reaccelerating above 3% or the stock stabilizing above $80.
ZTS is more suitable for long-term investment than short-term trading due to its low beta of 0.729, defensive characteristics, and dividend yield of 1.59%. The company is in a transition period, and it may take several quarters for growth to reaccelerate and for the market to regain confidence. Short-term traders could capitalize on volatility, but the stock's recent 54.2% max drawdown and 51.6% one-year decline highlight the risks of timing the market. A suggested minimum holding period is 2-3 years to allow for a full recovery in companion animal spending and the realization of new product cycles. Investors should monitor quarterly earnings and adjust their thesis accordingly.